Antares Pharma Announces Positive Results from Application Site Study for Anturol
EWING, N.J.--(BUSINESS WIRE)--Apr 19, 2007 - Antares Pharma, Inc. (AMEX: AIS) announced positive results from a recently completed site application study demonstrating that ANTUROL(R), it's oxybutynin ATD(TM) transdermal gel, was absorbed on a bioequivalent basis after a single-dose was applied to ...Healthcare Sales & Marketing Network News: Antares Reports On End of ...
Antares Reports On End of Phase II Meeting with FDA for Anturol(TM) (HSMN NewsFeed: Medical Devices, Pharmaceuticals and Diagnostics)News: Antares Pharma Receives Milestone Payment and Additional Patent ...
Antares Pharma, Inc. (AMEX:AIS) announced that the company received a milestone ... The Company's lead product candidate, Anturol™, an oxybutynin ATD™ gel for the ...News: Antares Reports On End of Phase II Meeting with FDA for Anturol ...
Antares Pharma, Inc. (Amex:AIS) announced that an end of Phase II meeting was held with the U.S. Food and Drug Administration (FDA), based on the positive Phase II ...AIS,TEVA Antares Pharma Receives Milestone Payment from Teva for Pen ...
TradingMarkets News for AIS,TEVA - Antares Pharma Receives Milestone ... The Company's lead product candidate, Anturol(TM), an oxybutynin ATD(TM) gel for ...